Circulating progenitor cells in patients with atrial fibrillation and their relation with serum markers of inflammation and angiogenesis

Summary

The pathophysiological inter-relationships and underlying ‘drivers’ of a prothrombotic state in atrial fibrillation (AF) are complex but may include endothelial abnormalities. Circulating progenitor cells (CPCs) have been recently described as a cell population that may promote repair of endothelial damage. We hypothesised abnormalities in this cell population, alongside abnormal markers of endothelial damage/dysfunction (von Willebrand factor, soluble E-selectin), apoptosis (soluble Fas, soluble Fas ligand), angiogenesis (vascular endothelial growth factor) and inflammation (interleukin-6) in 135 consecutive AF patients (14 with lone AF), who were compared to 33 ‘disease controls’ and 13 healthy controls. We also explored whether restoration of sinus rhythm would alter these indices. No significant differences in research indices were observed between AF and disease controls, apart from soluble Fas levels (p<0.001). Median CPC levels in lone AF were higher compared to ‘non-lone AF’ (that is, AF patients with co-morbidities) [p<0.001], apparently because of difference in age and presence of co-morbidities. There was an increase in CPC counts (p=0.007), but in not other markers following DC cardioversion. CPCs increased significantly in the 17 patients who were successfully cardioverted into sinus rhythm (p=0.003). In a stepwise multiple regression analysis, age (p=0.014), hyperlipidaemia (p=0.001) and use of statins (but not AF) was predictive of CPC counts (p=0.014). In conclusion, AF is unlikely to be independently associated with abnormalities in CPCs. Successful cardioversion is associated with a modest but significant increase in CPCs.

Keywords

Atrial fibrillation - angiogenesis - progenitor cells - apoptosis - inflammation

^* Drs. Watson and Shantsila contributed equally to this work and are joint 1st authors.

• References

• 1 Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009; 373: 155-166.
• 2 Felmeden D, Lip GYH. Endothelial function and its assessment. Expert Opin Investig Drugs 2005; 14: 319-336.
• 3 Freestone B, Chong AY, Nuttall S. et al. Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels. Thromb Res 2008; 122: 85-90.
• 4 Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008; 28: 1584-1595.
• 5 Case J, Mead LE, Bessler WK. et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol. 2007; 35: 1109-1118.
• 6 Seko Y, Nishimura H, Takahashi N. et al. Serum levels of vascular endothelial growth factor and transforming growth factor-beta1 in patients with atrial fibrillation undergoing defibrillation therapy. Jpn Heart J 2000; 41: 27-32.
• 7 Freestone B, Chong AY, Lim HS. et al. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis?. Ann Med 2005; 37: 365-372.
• 8 Choudhury A, Freestone B, Patel J. et al. Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and tissue factor in atrial fibrillation: a link among platelet activation, angiogenesis, and thrombosis?. Chest 2007; 132: 1913-1919.
• 9 Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007; 49: 741-752.
• 10 Shantsila E, Watson T, Lip GY. Antioxidant protection: yet another function of endothelial progenitor cells?. J Hum Hypertens 2007; 21: 343-346.
• 11 Tao J, Yang Z, Wang JM. et al. Shear stress increases Cu/Zn SOD activity and mRNA expression in human endothelial progenitor cells. J Hum Hypertens 2007; 21: 353-358.
• 12 Scharner D, Rössig L, Carmona G. et al. Caspase-8 is involved in neovascularization-promoting progenitor cell functions. Arterioscler Thromb Vasc Biol 2009; 29: 571-578.
• 13 Dai T, Zheng H, Fu GS. Hypoxia confers protection against apoptosis via the PI3K/Akt pathway in endothelial progenitor cells. Acta Pharmacol Sin 2008; 29: 1425-1431.
• 14 Gage BF, Waterman AD, Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc 2001; 285: 2864-2870.
• 15 Fuster V, Rydén LE, Cannom DS. et al. American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 08: 651-745.
• 16 Wang TJ, Massaro JM, Levy D. et al. A risk score for predicting stroke or death in individuals with newonset atrial fibrillation in the community: the Framingham Heart Study. J Am Med Assoc 2003; 290: 1049-1056.
• 17 Goon PK, Lip GY, Stonelake PS. et al. Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage / dysfunction / apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index. Neoplasia 2009; 11: 771-779.
• 18 Egan CG, Caporali F, Huqi AF. et al. Reduced levels of putative endothelial progenitor and CXCR4+ cells in coronary artery disease: kinetics following percut-aneous coronary intervention and association with clinical characteristics. Thromb Haemost 2009; 101: 1138-1146.
• 19 Choy JC, Granville DJ, Hunt DW. et al. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 2001; 33: 1673-1690.
• 20 Askenasy N, Yolcu ES, Yaniv I. et al. Induction of tolerance using Fas ligand: a doubleedged immunomodulator. Blood. 2005; 105: 1396-1404.
• 21 Nishino M, Hoshida S, Tanouchi J. et al. Time to recover from atrial hormonal, mechanical, and electrical dysfunction after successful electrical cardioversion of persistent atrial fibrillation. Am J Cardiol 2000; 85: 1451-1454.
• 22 Kamath S, Chin BS, Blann AD. et al. A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation. Blood Coagul Fibrinolysis 2002; 13: 627-636.
• 23 Giansante C, Fiotti N, Miccio M. et al. Coagulation indicators in patients with paroxysmal atrial fibrillation: effects of electric and pharmacologic cardioversion. Am Heart J 2000; 140: 423-429.
• 24 Freestone B, Chong AY, Blann AD. et al. The effects of direct current cardioversion for persistent atrial fibrillation on indices of endothelial damage/dysfunction. Thromb Res 2006; 118: 479-485.
• 25 Goette A, Jentsch-Ullrich K, Lendeckel U. et al. Effect of atrial fibrillation on hematopoietic progenitor cells: a novel pathophysiological role of the atrial natriuretic peptide?. Circulation 2003; 108: 2446-2449.
• 26 Takakura N, Kidoya H. Maturation of blood vessels by haematopoietic stem cells and progenitor cells: involvement of apelin/APJ and angiopoietin/Tie2 interactions in vessel caliber size regulation. Thromb Haemost 2009; 101: 999-1005.
• 27 Cesari F, Sofi F, Caporale R. et al. Relationship between exercise capacity, endothelial progenitor cells and cytochemokines in patients undergoing cardiac rehabilitation. Thromb Haemost 2009; 101: 521-526.
• 28 Smadja DM, Godier A, Susen S. et al. Endothelial progenitor cells are selectively mobilised immediately after coronary artery bypass grafting or valve surgery. Thromb Haemost 2009; 101: 983-985.
• 29 Di Stefano R, Barsotti MC, Melillo E. et al. The prostacyclin analogue iloprost increases circulating endothelial progenitor cells in patients with critical limb ischemia. Thromb Haemost 2008; 100: 871-877.
• 30 Spiel AO, Mayr FB, Leitner JM. et al. Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation. Thromb Res 2008; 123: 108-113.
• 31 Hristov M, Fach C, Becker C. et al. Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. Atherosclerosis 2007; 192: 413-420.
• 32 Case J, Mead LE, Bessler WK. et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007; 35: 1109-1118.
• 33 Rehman J, Li J, Orschell CM. et al. Peripheral blood „endothelial progenitor cells“ are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003; 107: 1164-1169.
• 34 Shantsila E, Watson T, Tse HF. et al. Endothelial colony forming units: are they a reliable marker of endothelial progenitor cell numbers?. Ann Med 2007; 39: 474-479.
• 35 Sieveking DP, Buckle A, Celermajer DS. et al. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J Am Coll Cardiol 2008; 51: 660-668.
• 36 Timmermans F, Van Hauwermeiren F, De Smedt M. et al. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol 2007; 27: 1572-1579.
• 37 Hirai H, Samokhvalov IM, Fujimoto T. et al. Involvement of Runx1 in the down-regulation of fetal liver kinase-1 expression during transition of endothelial cells to hematopoietic cells. Blood 2005; 106: 1948-1955.